Amgen AMGN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.82B+5.1% | $1.33B+113% | $3.22B+13.6% | $1.43B+92.0% | $1.73B+1,631% | ||
| $1.12B-19.5% | $1.13B-19.0% | $1.31B-6.4% | $1.34B-4.2% | $1.39B-0.9% | ||
| $75M-11.8% | $125M-6.7% | $127M-6.6% | $157M0.0% | $85M-17.5% | ||
| -$176M+29.6% | -$19M+94.3% | -$30M+72.7% | -$422M-10.2% | -$250M+37.7% | ||
| $0-100% | —— | $400M+556% | —— | $800M+1,076% | ||
| -$413M-132% | $1.08B+327% | $0-100% | $515M— | $1.31B+369% | ||
| -$18M+93.8% | -$119M+63.2% | -$240M+64.8% | -$239M+66.9% | -$288M+64.3% | ||
| $571M+14.9% | —— | —— | $589M-8.4% | $497M+2,061% | ||
| -$959M-9.7% | $749M+2.9% | -$200M+27.3% | $824M+18.9% | -$874M+17.1% | ||
| -$8M-104% | $577M+4,021% | $283M-5.4% | $206M-17.6% | $201M+126% | ||
| -$75M+3.8% | -$76M— | -$10M+74.4% | $0— | -$78M-39.3% | ||
| $67M+34.0% | -$250M-758% | $28M— | $23M— | $50M-73.7% | ||
| $71M-31.7% | -$365M— | —— | -$2.42B-57.6% | $104M-53.4% | ||
| -$143M-111% | —— | $1.97B+20.7% | —— | $1.3B+351% | ||
| $2.19B+57.4% | $1.6B-66.4% | $4.68B+31.2% | $2.28B-7.3% | $1.39B+102% | ||
| $712M+73.2% | $642M+73.0% | $436M+69.6% | $369M+55.0% | $411M+78.7% | ||
| $4M-88.9% | —— | —— | $20M+195% | $36M+377% | ||
| -$716M-60.2% | -$693M-72.4% | -$414M-97.1% | -$389M-79.3% | -$447M-106% | ||
| $1.36B+6.2% | $1.28B+6.5% | $1.28B+6.0% | $1.28B+5.9% | $1.28B+5.9% | ||
| $3.96B— | —— | —— | —— | $0— | ||
| $833M-66.7% | $0— | $1.5B-31.8% | $1B-28.6% | $2.5B— | ||
| -$104M-285% | —— | —— | -$92M-130% | -$27M+70.0% | ||
| $1.44B+135% | -$1.23B+12.9% | -$2.85B+21.9% | -$2.67B-0.9% | -$4.11B-140% | ||
| $2.91B+192% | -$316M-111% | —— | -$782M-92.1% | -$3.16B-156% | ||
| -$839M-273% | —— | $1.18B+27.4% | $627M+914% | $486M+254% | ||
| $71M+1.4% | $75M— | $74M— | $92M— | $70M+110% | ||
| -$8M-104% | $577M+4,021% | $283M-5.4% | $206M-17.6% | $201M+126% | ||
| $67M+34.0% | -$250M-758% | $28M— | $23M— | $50M-73.7% | ||
| $4M-88.9% | —— | —— | $20M+195% | $36M+377% | ||
| $233M-22.6% | $0— | $81M-67.5% | $301M— | $301M-26.6% | ||
| -$104M-285% | —— | —— | -$92M-130% | -$27M+70.0% | ||
| -$143M-111% | —— | $1.97B+20.7% | —— | $1.3B+351% | ||
| $1.48B+50.7% | $961M-78.2% | $4.25B+28.2% | $1.91B-14.0% | $980M+114% | ||
| $1.48B+50.7% | $961M-78.2% | $4.25B+28.2% | $1.91B-14.0% | $980M+114% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amgen generate?
- Amgen (AMGN) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Amgen's free cash flow?
- After $2.2B of capital expenditures, Amgen's free cash flow was $8.6B over the trailing twelve months, down 21.2% year over year.
- Where does Amgen's cash flow data come from?
- Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
